Acurx Pharmaceuticals
ACXP
26 hedge funds and large institutions have $3.05M invested in Acurx Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
13% more funds holding
Funds holding: 23 → 26 (+3)
13% more call options, than puts
Call options by funds: $117K | Put options by funds: $104K
0.03% more ownership
Funds ownership: 0.4% → 0.43% (+0.03%)
27% less capital invested
Capital invested by funds: $4.18M → $3.05M (-$1.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$277K |
| 2 |
LPL Financial
San Diego,
California
|
+$86.3K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
+$57.5K |
| 4 |
State Street
Boston,
Massachusetts
|
+$48.4K |
| 5 |
NS
NBC Securities
Birmingham,
Alabama
|
+$45.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$144K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$44.5K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$38.3K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$10.1K |
ACXP Hedge Fund Activity: Q1 2024 in Review
26 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2024, worth a combined $3.05M — down 27% from $4.18M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACXP positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $277K. The largest seller was BlackRock, cutting an estimated $144K.
- 26 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2024, up from 23 in Q4 2023.
- Funds reported $3.05M of Acurx Pharmaceuticals stock for Q1 2024, down 27% quarter-over-quarter.
- 8 funds opened new Acurx Pharmaceuticals positions in Q1 2024 and 5 closed out, a net change of +3 holders.
- The largest Acurx Pharmaceuticals buyer in Q1 2024 was Vanguard Group, an estimated $277K added.
- The largest Acurx Pharmaceuticals seller in Q1 2024 was BlackRock, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2024.